Business
Incannex Healthcare Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026
Company enters 2026 with over $70 million in cash, two positive Phase 2 programs, FDA Fast Track Designation and runway well into 2027MELBOURNE, Australia and NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, provides a 2025 corporate year-in-review and outlook for 2026, highlighting substantial clinical, regulatory and financial progress that positions the Company for conti
About this update from Incannex Healthcare Inc.
[{"type":"image","alt":"Incannex Healthcare","displaySize":"","headline":null,"caption":"Incannex Healthcare","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/27f6059234ed425fa359634ca773e7f7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JtZ_G8jXkVENc6BFL9UpGQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/27f6059234ed425fa359634ca773e7f7","width":300,"height":50}},"lazy":false},{"type":"text","content":"Company enters 2026 with over $70 million in cash, two positive Phase 2 programs, FDA Fast Track Designation and runway well into 2027","length":134,"tagName":"p"},{"type":"text","content":"MELBOURNE, Australia and NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, provides a 2025 corporate year-in-review and outlook for 2026, highlighting substantial clinical, regulatory and financial progress that positions the Company for continued execution.","length":381,"tagName":"p"},{"type":"text","content":"“The year 2025 was a defining one for Incannex,” stated Joel Latham, Incannex Healthcare Chief Executive Officer. “We delivered two independent, positive Phase 2 clinical readouts across distinct CNS programs, achieved FDA Fast Track designation for our lead OSA candidate, and materially strengthened our balance sheet. Importantly, we enter 2026 with more than $70 million in cash with runway extending well into 2027, allowing us to focus primarily on execution. With clinical validation, regulatory momentum and financial flexibility now in place, we are in a very exciting position as we advance our programs toward later-stage development and continue building long-term value for patients and shareholders.”","length":714,"tagName":"p"},{"type":"text","content":"2025 Corporate Highlights","length":25,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Two Positive Phase 2 Clinical Readouts across distinct CNS programs","length":67,"tagName":"p"}]},{"val":[{"type":"text","content":"FDA Fast Track Designation granted for lead obstructive sleep apnea candidate IHL-42X","length":85,"tagName":"p"}]},{"val":[{"type":"text","content":"Strengthened balance sheet with over $70 million in...